Title: Increased Long-Term Mortality in Patients Admitted to the Intensive Care Unit with Health-Care Associated Pneumonia

Running Title: Long-Term Pneumonia Mortality

Authors:

Kristin R. Wise, MD

Assistant Professor of Medicine

Medical University of South Carolina, Division of Internal Medicine and Geriatrics

Jordan A. Kempker, MD, MSc

Pulmonary and Critical Care

Emory University, Department of Medicine, Division of Pulmonary and Critical Care Medicine

Atlanta, GA

Radu F. Neamu, MD

Attending Pulmonologist

Bryan Medical Center

Lincoln, NE

Ketino Kobaidze, MD, Ph.D (corresponding author)

Associate Professor of Medicine

550 Peachtree Street, Atlanta, GA 30308

Cell: 404 840 4395

E- mail: kkobaid@emory.edu

Emory University, Department of Medicine, Division of Hospital Medicine

27 Atlanta, GA

28 **An institution where work was performed:** Emory University, Atlanta, GA

29 **Funding:** None for this current study. The creation of the original prospective cohort database
30 used in this study was funded by grants from the Carlyle Fraser Heart Center and the
31 Department of Medicine at Emory University. The funders had no role in the original study
32 design, data collection, data analysis, and interpretation, or manuscript writing.

33 **Keywords:** Healthcare-Associated Infection; Pneumonia; Mortality; Health Services Research;
34 Critical Illness

35 **Acknowledgments:** The authors have neither financial interests nor conflicts of interest to
36 disclose.

Summary of Key Points:

- The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) developed and periodically update guidelines for the diagnosis and management of community-acquired and nosocomial pneumonia based on the patient-care setting in which pneumonia evolved. ATS/IDSA provides guidelines for empiric antibiotic choices based on the category of pneumonia that is diagnosed.
- Pneumonia is a significant cause of mortality in the United States and when combined with influenza ranks as the eighth leading cause of death nationwide yet little is known about the mortality of critically ill patients with pneumonia that require admission to a medical intensive care unit (ICU).
- Our findings suggest that older age, higher severity of illness at ICU admission, and chronic comorbid illnesses are the main contributors to long-term mortality from pneumonia requiring ICU admission.
- In this cohort, we found an independent association between increased mortality and admission from the general hospital ward rather than directly from the emergency department.
- Our study did not demonstrate that initial guideline-based antibiotic therapy was associated with a reduction in short-term mortality; however, it did demonstrate a high prevalence of resistant pathogens in HCAP/HAP patients, which reflects ATS/IDSA guideline expectations.

Background: Pneumonia is a leading cause of death in the United States. Guidelines for its diagnosis and management are periodically updated, but long-term mortality in critically ill patients has not been well studied.

Objective: To determine differences in one-year mortality between patients with community-acquired pneumonia (CAP) and healthcare-associated pneumonia or hospital-acquired pneumonia (HCAP/HAP).

Methods: A retrospective multivariate analysis of a prospective cohort study that included all patients admitted to a single-center medical intensive care unit (ICU) from October 1, 2007, through September 30, 2008, with a diagnosis of pneumonia.

Results: There were 181 patients admitted to the medical ICU with a diagnosis of pneumonia, 58.0% with HCAP/HAP and 42.0% with CAP. Those with HCAP/HAP had an older age distribution and higher proportions of cardiovascular (79.1% vs. 63.2%, $P=0.02$) and neurological (36.2% vs. 18.4%, $P=0.01$) comorbidities. The HCAP/HAP patients demonstrated an increased risk of death within one a year in the unadjusted analysis (HR 1.6, 95% CI 1.1-2.2, $P=0.01$) that did not remain significant in the multivariate analysis (HR 1.3, 95% CI 0.80-2.10, $P=0.29$) when adjusting for simplified acute physiology score (SAPS) II score, age category, source of admission and a history of diabetes mellitus, neurological disease or malignancy.

Conclusion: Compared to patients admitted to a medical ICU with CAP, those with HCAP/HAP had a higher one-year mortality that is accounted for by the increased co-morbidities associated with a HCAP/HAP diagnosis.

INTRODUCTION

Pneumonia is a significant cause of mortality in the United States (US) and when combined with influenza ranks as the eighth leading cause of death nationwide, causing an estimated 50,000 deaths a year (1). In an effort to confront this public health concern, the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) developed and periodically update guidelines for the diagnosis and management of community-acquired and nosocomial pneumonias. In 2005, these guidelines outlined a different approach to what was previously known as nosocomial pneumonia, dividing it into three categories based on the patient-care setting in which the pneumonia evolved (2). These three categories are healthcare-associated pneumonia (HCAP), hospital acquired pneumonia (HAP) and ventilator-associated pneumonia. Similarly, specific guidelines were published in 2007 to help clinicians with the management of community acquired pneumonia (CAP) (3).

Since publication, these guidelines have spurred research into the efficacy and safety of their treatment recommendations for each pneumonia class as well as their ability to identify patients at risk for drug-resistant pathogens and higher mortality (4-26). In regards to the latter, six studies have examined mortality differences among the different pneumonia types in hospitalized patients and have shown heterogeneous results (8, 11, 12, 14, 18, 22). Among these studies, there is a paucity of data specifically examining critically ill patients and long-term mortality. To our knowledge, only one recent study has examined this question, demonstrating that pneumonia type for patients admitted to the intensive care unit (ICU) was associated with long term mortality but not short term mortality (12). Given the high incidence of this morbid disease, further information is needed regarding the outcomes of the of the various types of pneumonias presenting to the ICU to better identify the burden of disease they each represent to the community and to help prognosticate for individual patients. In this study, we compared the one-year survival among patients admitted to the medical ICU with CAP, HCAP, and HAP and examined the patient characteristics that are associated with mortality.

MATERIALS AND METHODS

Study population

This study is a retrospective analysis of a previously collected prospective cohort of patients admitted to the medical ICU from October 1, 2007, through September 30, 2008, at a single center 511-bed urban, an academic hospital in Atlanta, Georgia. The details regarding the patient population in the above-mentioned database are described elsewhere (27). The study proposal was approved by the Emory University Institutional Review Board.

All adult patients admitted to the ICU within the above period with a diagnosis of pneumonia were included in the study. We excluded patients admitted to the medical ICU with ventilator-associated pneumonia (which generally encompassed patients with tracheostomies from ventilator weaning facilities) and those who did not meet criteria for pneumonia based on documented evidence of a new radiographic infiltrate plus documentation of at least two of the following signs or symptoms: 1) white blood cell count $>10,000/\text{ml}$ or $<4,000/\text{ml}$; 2) temperature $> 38.3^{\circ}$ or $< 35^{\circ}$ Celsius; 3) purulent secretions from the lower respiratory tract; or 4) new-onset or worsening of dyspnea, oxygen requirements or altered mental status.

Data Sources and Variables

All data were gathered from the electronic medical record by study investigators and entered into an Excel spreadsheet (Microsoft Corporation). The primary variable of interest was the pneumonia type on admission to the medical ICU. Diagnoses of CAP, HCAP, and HAP were determined by study investigators based on documented evidence of criteria according to the 2005 ATS/IDSA guideline definitions (2). Furthermore, the diagnosis of HAP required the documented absence of an infiltrates on a chest x-ray at the initial hospital admission with the development of a new infiltrate upon transfer to the medical ICU. The primary outcome of interest was one-year all-cause mortality, which was determined by linking patients to their corresponding death records with the US Social Security database.

Patient characteristics collected from the electronic medical record included age, gender, race (self-identified), medical co-morbidities, and source of ICU admission. The severity of illness scores, acute physiology, and chronic health evaluation (APACHE) II and simplified acute physiology score (SAPS) II, were calculated using the standard formula with physiologic variables from the time of the ICU admission. For microbiologic data, we recorded the results of the first blood cultures collected during the period from 6 hours before arrival to the ICU until 3 days after. To capture the etiology for pneumonia, all lower respiratory tract (LRT) cultures obtained during the first 5 days after ICU admission were recorded. An LRT culture was defined as a tracheal aspirate, bronchoalveolar lavage (BAL), bronchial wash, protected brush specimen, or mini-BAL. A multi-drug resistant (MDR) gram-negative pathogen was defined as one with documented decreased susceptibility to at least two of the antibiotic classes recommended for treating pneumonia as delineated by the 2005 ATS/IDSA guidelines (2).

For treatment variables, we recorded all antibiotics administered during the period of 12 hours before arrival in the ICU through ICU discharge. Antibiotic appropriateness was determined by antibiotics given at ICU admission and deemed inappropriate if: 1) they did not include the recommended antibiotic classes for CAP, HCAP, and HAP in the 2005 and 2007 ATS/IDSA guidelines, including double coverage for *Pseudomonas aeruginosa* for HCAP and HAP and atypical coverage for CAP, or 2) they included antibiotics outside of those recommended for respective pneumonia (i.e., using HCAP coverage for CAP). Other treatment variables collected include the use and duration of noninvasive or invasive mechanical ventilation. Outcomes recorded included ICU and hospital length of stay and mortality.

Statistical Analysis

All data analyses were performed using SAS 9.3 (SAS Institute Inc. Cary, NC) statistical software. We initially intended to compare CAP, HAP, and HCAP as separate categories, but only 15 (8.0%) subjects had HAP. Therefore, HAP and HCAP were combined for analysis and are referred to as HCAP/HAP in our study. For the bivariate analyses, categorical variables

were compared with a chi-square test or Fisher's exact test. Continuous variables with a normal distribution were compared with a two-tailed t-test. Continuous variables with a non-normal distribution were compared using the Wilcoxon Ranked Sum test. The model for the multivariate analysis was constructed using the covariate selection method described by Hosmer and Lemeshow and is briefly described here (28). Covariates were initially selected for model inclusion if they were associated with both the primary outcome and exposure at a p-value < 0.25 in the bivariate analyses. Then, covariates were retained in the model for a p-value < 0.10 or if upon removal from the model, the pneumonia classification parameter estimate did not change by $\geq 20\%$. Then each covariate from the entire dataset was entered into this reduced model and retained if they changed the pneumonia classification parameter estimate by $\geq 20\%$. Final p-values of <0.05 were considered statistically significant.

RESULTS

Patient Characteristics

During the study period, 1,357 patients were admitted to the medical ICU of which 181 (13.3%) carried a diagnosis of pneumonia. There were 105 (58.0%) patients with HCAP/HAP and 76 (42.0%) with CAP. Table 1 compares the baseline demographics, preexisting comorbidities, and clinical stay characteristics of CAP and HCAP/HAP patients. When compared to CAP, patients with HCAP/HAP had a significantly older age distribution and higher proportions of cardiovascular (79.1% vs. 63.2%, $P=0.02$) and neurological (36.2% vs. 18.4%, $P=0.01$) comorbidities. There were trends towards higher APACHE II and SAPS II scores in HCAP/HAP patients (23.7 vs. 21.8, $P=0.07$ and 45.4 vs. 41.5, $P=0.08$, respectively).

Main Findings

The one-year survival for critically ill pneumonia patients and their characteristics associated with mortality are shown in Table 2 and their Cox proportional survival curves are depicted in Figure 1. The one-year crude mortality of HCAP/HAP and CAP patients was 62.0%

and 34.0%, respectively. HCAP/HAP patients had an increased risk of death within one year in the unadjusted analysis (HR 1.6, 95% CI 1.1-2.2, P=0.01). This finding did not remain statistically significant in the multivariate analysis (HR 1.3, 95% CI 0.8-2.1, P=0.29) when adjusting for SAPS II score, age category, source of ICU admission, and preexisting conditions of diabetes mellitus, neurological disease or malignancy (Table 2). We performed a secondary, exploratory analysis examining mortality at different time points, showing an increase in unadjusted mortality among HCAP/HAP patients at 60 days, but not at 30 or 90 days (Table 3). We ran our multivariable model with the 60-day outcome and again HCAP/HAP did not remain a significant risk factor for mortality.

Microbiology of Pneumonias and Antibiotic Treatment

Cultures were not performed in 5.7% and 5.3% of HCAP/HAP and CAP patients, respectively. The first culture obtained was a blood culture in the majority of both HCAP/HAP (84.8%) and CAP (81.6%) patients. Lower respiratory cultures were performed in 32.4% of HCAP/HAP and 27.6% of CAP patients. Figure 2 summarizes the microbiology of the pneumonias in the study group. Blood and respiratory tract cultures remained negative in 52.6% of CAP patients and 43.8% of HCAP/HAP patients. Methicillin-resistant *Staphylococcus aureus* (MRSA) and MDR gram-negative bacilli were not cultured among the CAP patients while these organisms comprised the infectious agent in 6.7% and 3.8% of the HCAP/HAP patients, respectively.

When compared to HCAP/HAP patients, those with CAP were more likely to have the appropriate initial antibiotic therapy at admission to the ICU (38.2% vs. 17.1%, P<0.01) as shown in Table 1. However, appropriate antibiotics did not affect one-year mortality, with 27.1% of the survivors and 25.0% of non-survivors receiving appropriate antibiotics (P=0.75).

Other Outcomes

Invasive mechanical ventilation was required in 38.1% of the CAP patients and 38.1% of the HCAP/HAP patients (Table 1). There were no significant differences in the use of non-invasive positive pressure ventilation or ICU or hospital length of stay between the two pneumonia groups.

DISCUSSION

This study compares the characteristics and outcomes between patients admitted to a single-center medical ICU with a diagnosis of CAP or HCAP/HAP over one year. Patients with HCAP/HAP were older with more medical comorbidities and more resistant pathogens. While our study identified that the HCAP/HAP patients had an increased, unadjusted one-year mortality when compared to CAP, this finding did not persist when adjusted for SAPS II score, age, source of ICU admission and preexisting diabetes mellitus, neurological disease, or malignancy. These findings suggest that older age, higher severity of illness at ICU admission, and chronic comorbid illnesses are the main contributors to long-term mortality from pneumonias requiring ICU admission.

We compared our mortality findings with the existing literature, which focuses mostly on short-term mortality. To date, we know of only one study that has examined long-term mortality by pneumonia type in patients admitted to ICU. This study demonstrated no difference in adjusted short-term mortality but showed a higher unadjusted one-year mortality among patients with HAP (12). This may be similar to our unadjusted findings of an increased risk of death within one year for HCAP/HAP patients that did not remain statistically significant in our multivariate analysis. While five studies have found that HCAP carries higher unadjusted mortality, this association remained in only one of the three studies that adjusted for confounders. Not surprisingly, these data have also shown that patients with HCAP are older with more severe chronic comorbidities and often present with more severe illness (8, 11, 14, 18, 22). In regards to the effects of comorbid illnesses, one study examining the long-term

mortality of patients hospitalized with CAP also found that older age, cerebrovascular disease, and cardiovascular disease were associated with increased mortality (29). Overall, the sum of these data, combined with our study results, suggest that the current pneumonia classification is not an independent risk factor for mortality but rather a marker of more chronic and severe illness.

In addition to our main results, our study identified several other interesting findings. In this cohort, we found an independent association between increased mortality and admission from the general hospital ward rather than directly from the emergency department. A similar association was found in one study that examined the source of ICU admission for patients with septic shock (30). In that study, in comparison to patients admitted from the general ward, those from the emergency department had lower in-hospital mortality, less mechanical ventilation utilization, and shorter times to achieving ScVO₂ goals (30). As our study was not designed to compare the differences between patients admitted to the medical ICU from these two sources, we can only speculate as to whether treatment in the emergency department was protective or whether admission from the hospital ward was confounded by co-morbid and concurrent illness.

Finally, our study did not demonstrate that initial guideline-based antibiotic therapy was associated with a reduction in short-term mortality; however, it did demonstrate a high prevalence of resistant pathogens in HCAP/HAP patients, which reflects ATS/IDSA guideline expectations. There were no cultures positive for MDR gram-negative bacilli or MRSA among ICU patients with CAP while these organisms were present in 10.5% of HCAP/HAP patients. The existing published literature demonstrates varying conclusions with only a portion of the studies showing a high prevalence of *Pseudomonas aeruginosa* and MRSA in both HCAP and CAP patients (4, 19, 25, 26, 31). Such discrepancies may explain the inconsistent reported results on the association between guideline-based antibiotic therapy and mortality (7, 10, 13, 15-17, 23, 24). Other investigators have sought alternate means to identify those at higher risk

of resistant pulmonary pathogens although significant research is still needed in this area (6, 9, 20, 21).

There are limitations to the present study that must be noted. This is a single-center study and as the microbiology of pneumonia may vary according to the setting, our results may not be generalizable. Although the initial cohort was captured prospectively, study investigators determined the diagnoses of pneumonia on retrospective chart review. While the use of specific criteria to define the various pneumonia types increases internal validity, there may be confounding factors in original medical documentation that led to misclassification errors in the study. Furthermore, the retrospective design may have limited an aggressive approach to the microbiologic diagnosis of pneumonia, resulting in a lower proportion of patients with a LRT culture. Despite these limitations, this study continues research in an important area and is able to provide additional data regarding the clinical characteristics, microbiologic findings and mortality outcomes of patients admitted to ICU with a diagnosis of pneumonia obtained from a realistic practice setting.

CONCLUSION

This study demonstrates higher one-year mortality among patients admitted to a medical ICU with HCAP/HAP compared to those admitted with CAP that is likely accounted for by the increased co-morbidities associated with a HCAP/HAP diagnosis. Further evidence is needed to distinguish the true, and likely evolving, microbiologic relevance of the distinction between HCAP/HAP and CAP to guide future treatment recommendations.

References

1. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59(10):1-126.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
4. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162(16):1849-58.
5. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878-87.
6. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22(3):316-25.
7. Capelastegui A, Espana PP, Quintana JM, Gorordo I, Ortega M, Idoiaga I, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis. 2004;39(7):955-63.
8. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53(2):107-13.

9. El Solh AA, Pietrantonio C, Bhat A, Bhora M, Barbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. *Clin Infect Dis*. 2004;39(4):474-80.
10. Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. *Clin Ther*. 2010;32(2):293-9.
11. Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poirier MS, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. *J Antimicrob Chemother*. 2011;66(7):1617-24.
12. Karhu J, Ala-Kokko TI, Ylipalosaari P, Ohtonen P, Laurila JJ, Syrjälä H. Hospital and long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilator-associated pneumonia patients. *Acta Anaesthesiol Scand*. 2011;55(10):1254-60.
13. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. *Lancet Infect Dis*. 2011;11(3):181-9.
14. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest*. 2005;128(6):3854-62.
15. Lancaster JW, Lawrence KR, Fong JJ, Doron SI, Garpestad E, Nasraway SA, et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. *Pharmacotherapy*. 2008;28(7):852-62.
16. Madaras-Kelly KJ, Remington RE, Sloan KL, Fan VS. Guideline-based antibiotics and mortality in healthcare-associated pneumonia. *J Gen Intern Med*. 2012;27(7):845-52.
17. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. *Arch Intern Med*. 2009;169(16):1525-31.

- 331 18. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated
332 pneumonia and community-acquired pneumonia: a single-center experience. *Antimicrob Agents*
333 *Chemother.* 2007;51(10):3568-73.
- 334 19. Quartin AA, Scerpella EG, Puttagunta S, Kett DH. A comparison of microbiology and
335 demographics among patients with healthcare-associated, hospital-acquired, and ventilator-
336 associated pneumonia: a retrospective analysis of 1184 patients from a large, international
337 study. *BMC infectious diseases.* 2013;13:561.
- 338 20. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-
339 resistant bacteria by select risk factors for health care-associated pneumonia. *Arch Intern Med.*
340 2008;168(20):2205-10.
- 341 21. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a
342 clinical score for assessing the risk of resistant pathogens in patients with pneumonia
343 presenting to the emergency department. *Clin Infect Dis.* 2012;54(2):193-8.
- 344 22. Venditti M, Falcone M, Corrao S, Licata G, Serra P, Medicine SGotISol. Outcomes of
345 patients hospitalized with community-acquired, health care-associated, and hospital-acquired
346 pneumonia. *Ann Intern Med.* 2009;150(1):19-26.
- 347 23. Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR. Guideline-concordant
348 antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. *Respir Med.*
349 2012;106(11):1606-12.
- 350 24. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy
351 escalation and hospital mortality among patients with health-care-associated pneumonia: a
352 single-center experience. *Chest.* 2008;134(5):963-8.
- 353 25. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not
354 accurately identify potentially resistant pathogens: a systematic review and meta-analysis. *Clin*
355 *Infect Dis.* 2014;58(3):330-9.

26. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2013;57(10):1373-83.
27. Wise KR, Akopov VA, Williams BR, Ido MS, Leeper KV, Dressler DD. Hospitalists and intensivists in the medical ICU: a prospective observational study comparing mortality and length of stay between two staffing models. J Hosp Med. 2012;7(3):183-9.
28. Hosmer D, Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event data. Hoboken, NJ: Wiley-Interscience; 2008.
29. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169(8):910-4.
30. Wang Z, Schorr C, Hunter K, Dellinger RP. Contrasting treatment and outcomes of septic shock: presentation on hospital floors versus emergency department. Chin Med J (Engl). 2010;123(24):3550-3.
31. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S81-7.

Table 1. Patient Characteristics by Pneumonia Type in Adults Admitted to a Medical Intensive Care Unit.

Variable	CAP <i>n</i> = 76	HCAP/HAP <i>n</i> = 105	P value
Demographic Characteristics			
Age, years, <i>n</i> (%)			0.01
< 35	7 (9.2)	8 (7.6)	
35-49	21 (27.6)	11 (10.5)	
50-64	17 (22.4)	44 (41.9)	
65-80	18 (23.7)	25 (23.8)	
> 80	13 (17.1)	17 (16.2)	
Gender, female, <i>n</i> (%)	33 (43.4)	56 (53.3)	0.19
Race, black, <i>n</i> (%)	54 (71.1)	79 (75.2)	0.81
Preexisting Comorbidities			
Past Medical History, <i>n</i> (%)			
Cardiovascular Disease	48 (63.2)	83 (79.1)	0.02
Pulmonary Disease	24 (31.6)	45 (42.9)	0.12
Diabetes Mellitus	24 (31.6)	45 (42.9)	0.12
Chronic Kidney Disease	17 (22.4)	32 (30.5)	0.23
Neurological Disease	14 (18.4)	38 (36.2)	0.01
Malignancy	12 (15.8)	18 (17.1)	0.81
Human Immunodeficiency Virus	13 (17.1)	15 (14.3)	0.60

Gastroenterological Disease	13 (17.1)	17 (16.2)	0.87
Morbid Obesity (BMI ≥40)	4 (5.3)	8 (7.6)	0.53
Immunocompromise	5 (6.6)	5 (4.8)	0.60
Clinical Stay Characteristics			
Location before ICU Transfer, n (%)			0.06
Emergency Department	53 (69.7)	59 (56.2)	
General Hospital Ward	23 (30.3)	46 (43.8)	
APACHE II Score, mean ±SD	21.8 ± 6.9	23.7 ± 7.2	0.07
SAPS II Score, mean ±SD	41.5 ± 15.1	45.4 ± 14.3	0.08
Appropriate Empiric Antibiotics, n (%)	29 (38.2)	18 (17.1)	<0.01
Lower Respiratory Culture Obtained, n (%)	21 (27.6)	34 (32.4)	0.49
MDR Organism Identified, n (%)	2 (2.6)	12 (11.4)	0.05
Endotracheal Intubation, n (%)	29 (38.1)	40 (38.1)	1.0
Noninvasive Ventilation, n (%)	23 (30.3)	34 (32.4)	0.76
ICU Length of Stay, median days (IQR)	3 (2.0-7.0)	4 (2.0-8.0)	0.41
Hospital Length of Stay, median days (IQR)	9 (5.7 -13.6)	9.8 (5.3-19.7)	0.35

APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CAP, community-acquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; ICU, intensive care unit; IQR, Inter-quartile range; SAPS, simplified acute physiology score; MSSA, Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; MDR, Multi-drug resistant.

Table 2. Multivariate Cox Proportional Hazards Model for Time from Intensive Care Unit Admission to Death within One Year Among Patients Admitted to a Medical Intensive Care Unit with Pneumonia, N = 181, Likelihood Ratio Test $p < 0.0001$.

Variable	Hazard Ratio (95% CI)	P value
HCAP/HAP vs. CAP	1.30 (0.80-2.10)	0.29
SAPS II Score	1.02 (1.01-1.04)	<0.01
Admitted From General Hospital Ward vs. ED	1.66 (1.05-2.49)	0.03
Age Category		
< 35	Referent	
35-49	0.81 (0.28-2.40)	0.70
50-64	1.04 (0.39-2.80)	0.94
65-80	1.54 (0.57-4.17)	0.39
> 80	1.92 (0.69-5.39)	0.21
Preexisting Comorbidities		
Neurological Disease	0.98 (0.59-1.62)	0.94
Diabetes Mellitus	0.72 (0.40-1.12)	0.14
Malignancy	2.70 (1.61-4.51)	<0.01

CAP, community-acquired pneumonia; ED, emergency department; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; SAPS, simplified acute physiology score.

Table 3, Exploratory Analysis of Different Mortality Endpoints in Patients with Pneumonia Admitted to the Intensive Care Unit by Pneumonia Type.

Mortality Endpoint	CAP Mortality n (%)	HCAP/HAP Mortality n (%)	Unadjusted RR (95%CI) HCAP/HAP v. CAP	P value
ICU	7 (9.2)	14 (13.3)	1.3 (0.7-2.4)	0.39
30-Day	17 (22.4)	33 (31.4)	1.3 (0.9-2.1)	0.18
60-Day	17 (22.4)	43 (41.0)	1.7 (1.1-2.7)	0.09
90-Day	23 (30.3)	46 (43.8)	1.4 (1.0-2.1)	0.06
One Year	32 (42.1)	64 (61.0)	1.6 (1.1-2.2)	0.01

CAP, community-acquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; ICU, intensive care unit.

Figure 1. Cox Proportional Survival Curves for Mortality From Intensive Care Unit (ICU) Admission to One Year Among Patients with Pneumonia Admitted to a Medical ICU. Stratified by Pneumonia Type and Adjusted for Simplified Acute Physiology Score (SAPS) II, Location Before Admission, Age Category and Preexisting of Neurological Disease, Diabetes Mellitus and Malignancy. N = 181.

Figure 2. Pathogens Detected in Respiratory and Blood Cultures According to Pneumonia Type. The other category included yeast, nontuberculous mycobacterial species, unidentified gram positive cocci and pneumocystis jirovecii in decreasing order of frequency. CAP, community-acquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; MSSA, Methicillin-sensitive *Staphylococcus aureus*; MRSA, Methicillin-resistant *Staphylococcus aureus*; MDR, Multi-drug resistant.